Concepedia

Publication | Closed Access

A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors

DOI

136

Citations

26

References

2010

Year

Roy S. Herbst, Razelle Kurzrock, David S. Hong, Manuel Valdivieso, Cheng‐Pang Hsu, Lovely Goyal, Gloria Juan, Yuying C. Hwang, F. Susan Wong, John S. Hill,
Clinical Cancer Research

Abstract

Conatumumab can be administered safely up to the target dose of 20 mg/kg every 2 weeks.

References

YearCitations

Page 1